Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapcabtagene Autoleucel for MRD in Large B-Cell Lymphoma
NCT07443137Phase 1Recruiting
- Sponsor
- Stanford University
- Start
- Sep 2026
- Primary completion
- Aug 2028
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of rapcabtagene autoleucel in diffuse large B-cell lymphoma (DLBCL) (2 cohorts), sponsored by Stanford University. Primary endpoint: Minimal Residual Disease Conversion Rate at Day 90. Started Sep 2026; status: recruiting.
02
Drugs
rapcabtagene autoleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07443137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07443137.